Related Experiment Videos
Long-term intraperitoneal deferoxamine for hemochromatosis
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, 48109-0364, USA.
The American Journal of Medicine
|March 1, 1996
Summary
Intraperitoneal deferoxamine effectively treated iron overload in a patient with secondary hemochromatosis. This approach, using a peritoneal dialysis catheter, reversed clinical and biochemical indicators of iron overload over two years.
Area of Science:
- Nephrology
- Hepatology
- Cardiology
Background:
- Intraperitoneal deferoxamine is standard for aluminum toxicity in end-stage renal disease patients on peritoneal dialysis.
- Its use outside chronic renal failure for other conditions is not well-documented.